MedTrace Logo

Serine Supplementation for Obese Subjects With Fatty Liver Disease

NCT02599038 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-10-18

No results posted yet for this study

Summary

In this study, the investigators aim to increase the liver tissue level of GSH in NAFLD patients by short-term dietary serine supplementation and improve their liver function by lowering the oxidative stress resulting from hepatic steatosis.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

DIETARY_SUPPLEMENT

Serine supplementation

Serine supplementation (200 mg/kg/day)

Sponsors & Collaborators

  • Hanns-Ulrich Marschall

    lead OTHER

Principal Investigators

  • Hanns-Ulrich Marschall, MD, PhD · Sahlgrenska Academy and University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02599038 on ClinicalTrials.gov